key: cord-0792092-1bqsvxf1 authors: Pinto, Erika Gracielle; Barbosa, Leandro R.S.; Mortara, Renato A.; Tempone, Andre Gustavo title: Targeting intracellular Leishmania (L.) infantum with nitazoxanide entrapped into phosphatidylserine-nanoliposomes: An experimental study date: 2020-10-20 journal: Chem Biol Interact DOI: 10.1016/j.cbi.2020.109296 sha: 5546087b57320c9b443b0536b95598a5a210deda doc_id: 792092 cord_uid: 1bqsvxf1 Leishmaniasis is a parasitic neglected tropical disease and result in a broad spectrum of clinical manifestations, ranging from a single ulceration to a progressive and fatal visceral disease. Comprising a limited and highly toxic therapeutic arsenal, new treatments are urgently needed. Targeting delivery of drugs has been a promising approach for visceral leishmaniasis (VL). Phosphatidylserine-liposomes have demonstrated superior efficacy in VL, targeting intracellular parasites in host cells through macrophage scavenger receptors. In this work, we investigated the in vitro and in vivo efficacy of the antihelminthic drug nitazoxanide in a nanoliposomal formulation against Leishmania (L.) infantum. Physicochemical parameters of liposomes containing nitazoxanide (NTZ-LP) were determined by dynamic light scattering and small angle X-ray scattering. The efficacy of the formulation was verified in an intracellular amastigote model and in an experimental hamster model. Our findings showed that NTZ-LP was able to eliminate the amastigotes inside the host cell with an IC(50) value of 16 μM. NTZ-LP was labelled a fluorescent probe and by spectrofluorimetry, we observed that the infected macrophages internalized similar levels of the drug to the uninfected cells. The confocal microscopy images confirmed the uptake and demonstrated a diffuse distribution of the NTZ-LP in the cytoplasm of Leishmania-infected macrophages, with the vesicles in a closer proximity to the parasites. For the in vivo efficacy, the liposomal NTZ-LP was administrated intraperitoneally to Leishmania-infected hamsters for 10 consecutive days at 2 mg/kg/day. By qPCR we demonstrated a reduction of the parasite burden by 82% and 50% in the liver (p < 0.05) and spleen (p < 0.05), respectively. NTZ (non-liposomal) was administered at 100 mg/kg/day per oral (p.o.) for the same period, but demonstrated no efficacy. This liposomal formulation ensured a targeting delivery of NTZ to the intracellular parasites, resulting in an good efficacy at a low dose in animals, and it may represent a new candidate therapy for VL. The repositioning of drugs has been widely explored in the last years in all pharmaceutical fields. In the case of neglected tropical diseases (NTDs) that affect poor population in developing countries, it could be considered an excellent opportunity to reduce the costs and time for a new alternative therapy. Leishmaniasis is a protozoal parasitic disease caused by Leishmania spp. and is included among the six most important NTDs for the WHO [1] . The disease causes a spectrum of clinical manifestations depending of the parasite specie, ranging from a single cutaneous ulceration to a fatal and progressive visceral form. It affects 12 million people in 98 countries, with a global incidence estimated at approximately 0.9-1.6 million cases occurring each year [1] . Clinical therapy has many limitations, including restrict and old arsenal of drugs, causing serious adverse effects and relapses. The co-infections of visceral leishmaniasis (VL) with HIV induces a dramatic immunosuppression, resulting in less effective treatments; only co-administrations have been shown to improve treatment [2] . Nitazoxanide (NTZ) [2-(Acetyloxy)-N-(5-nitro-2-thiazolyl)benzamide], was originally discovered in the 1970s, first used as a veterinary anthelmintic agent for intestinal protozoa and later to treat human helminths [3] [4] . Approved in 2002 by the United States Food and Drug Administration (FDA) against cryptosporidiosis (Cryptosporidium species) and giardiasis (Giardia intestinalis), it is commercialized as Alinia ® or Annita ® as an oral suspension and/or tablets [5] . Nitazoxanide is a compound belonging to the thiazolides, composed by a nitrothiazole-ring and a salicylic acid moiety linked by an amide. This chemical group has been showing success against a broad variety of parasites, anaerobic bacteria and viruses. Recently, the drug was proposed as a candidate against coronavirus-2 (SAR CoV 2) in a combination therapy with hydroxychloroquine [6] and azithromycin [7] . Belardo and co-workers [8] showed the activity of NTZ against influenza A virus (H1N1, H3N2, H5N9, H7N1) [9] ; NTZ has also shown anti-cancer activity [4] , anti-coronavirus activity, anti-HIV activity [10] as well as anti-nematode activity [11] . The in vivo anti-Leishmania donovani activity of nitazoxanide had been described by Zhang and co-workers J o u r n a l P r e -p r o o f of 400 mg/kg in a murine experimental model (BALB/c). However, the bioavailability of nitazoxanide is limited due to its poor water solubility [13] . Development of drug delivery system is an essential practice to increase the safety and reduce the toxicity of drugs and has been a promising approach for cancer [14] , but also for infectious diseases as leishmaniasis [15] . Due to a poor bioavailability and targeting, including other interferences (e.g. metabolism, degradation), many drugs lose activity after oral administration [16] , but delivery systems like liposomes can improve the efficacy. Liposomal amphotericin B has been used for many years in the clinical treatment of leishmaniasis, reducing doses and toxicity of the drug [2] . The benefit of a liposomal formulation is mainly attributed to the targeting ability, consequently reducing the amount of free drug in the body and the toxicity [17] [18] . The interaction of liposomes with the target cells is the key feature to consider when designing a controlled release system [19] . The targeting of nanoliposomes containing negatively charged phosphatidylserine (PS) to mononuclear phagocytes cells has been shown promising results [20] . This is due to a specific class of macrophage scavenger receptors (CD36 and SR-B) responsible for the rapid binding and uptake of these liposomes [21] [22] . Based in this concept, the FDAapproved drug nitazoxanide was entrapped into negatively charged PS-nanoliposomes and evaluated against Leishmania (L.) infantum in ex vivo and in vivo models. supplemented with 10% fetal bovine serum (FBS, Gibco), 0.25% hemin (Sigma-Aldrich) and 5% human urine at 24°C. Amastigotes were obtained from the spleen of golden hamsters previously infected and purified by differential centrifugation. Peritoneal macrophages were collected by washing the peritoneal cavity of BALB/c mice with RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% FBS and were maintained at 37°C in a 5% CO 2 humidified incubator. [20] . Miltefosine was used as standard drug and untreated cells as a negative control. Peritoneal macrophage (6x10 4 cells/well), seed in 96-well plates were incubated with the compounds up to 200 μM in a 5% CO 2 humidified incubator at 37°C. The 50% Cytotoxic Concentration (CC 50 ) was determined by the colorimetric MTT method [23] . The selectivity index was determined using the following equation: CC 50 against NCTC cells/IC 50 against amastigotes 2.6. Nitazoxanide entrapment in liposomes. Liposomes were prepared by the lipid hydration method followed by freeze-thawing [24] . For liposomes preparation, saturated egg phosphatidylcholine, phosphatidylserine and cholesterol were used at a 7:2:1 molar ratio. the peritoneal cavity of BALB/c mice, were seeded at 1x10 5 /well in a black 96-well microplate and incubated at 37°C in a humidified 5% CO 2 incubator for 24 h. Leishmania (L.) infantum amastigotes were previously isolated from the spleen of infected hamsters, separated by differential centrifugation and added to the macrophages at a ratio of 1:10 (macrophage/amastigotes). Non-infected macrophages were used as control. After 24 hours of incubation, liposomal nitazoxanide labelled with the fluorescent probe DIL C18 (NTZ-LP-DIL) and the uptake was monitored in a spectrofluorimeter (FilterMax 5 Molecular Devices) every 15 minutes over 360 minutes, using excitation and emission filters of 549 and 565 nm, respectively [26] . Peritoneal macrophages were applied (1x10 5 /well) to 16-well slide chambers (Nunc ® ) and infected with L. (L.) infantum amastigotes at a ratio 1:10 (macrophage/amastigotes) for 24 h at 37°C, as previously described. Liposomal nitazoxanide DIL (NTZ-LP-DIL) was prepared in the presence of the fluorescent marker DIL (C18) and incubated with infected macrophages for 3 h at 37°C. The cells were washed with PBS, fixed with 4% formaldehyde, stained with DAPI (1mM) and processed for confocal microscopy. A giemsa-stained slide chambers was prepared to confirm the parasite burden. The samples were imaged on a Bio-Rad 1024-UV confocal system (Bio-Rad Hercules, CA) using a 100× 1.4 NA oil immersion objective with phase contrast. Image J software (http://rsb.info.nih.gov/ij/) was used to analyse fluorescence intensity distributions, to adjust contrast or brightness of acquired images and to combine images. Sequential where k B is the Boltzmann constant, T is the absolute temperature, η is the viscosity of the solvent, D h and D app are the hydrodynamic diameter and the apparent translational diffusion coefficient, respectively [26] . SAXS data analysis for liposome-like structures can be theoretically evaluated supposing that the liposome diameter is much larger size then the X-ray wavelength, λ. Under such assumption, the scattering curve can be described by an infinite plane with a nonhomogeneous cross section in the z direction and across the membrane bilayer [29, 30] .The scattering intensity can be written as: J o u r n a l P r e -p r o o f Where k is a normalization constant, n p is the lipid concentration, q is the scattering vector and P t (q) is the bilayer cross-section form factor. In this study, P t (q) was calculated supposing the three-step model [30] . In this case, each leaf let of the bilayer is composed by three different electron density profiles: the inner methyl group, or CH 3 region, the subsequent paraffinic chains (or alkyl chains) and the outer polar head group. Moreover, each region has it on electron density value and thickness: ρ pol is the electron density for the polar head group, whereas ρ CH 2 and ρ CH 3 are the electron density of the alkyl chain and the CH 3 regions, respectively. The thicknesses are: R pol , R CH 2 and R CH 3 for the polar head group, the paraffinic chains and for the CH 3 region, respectively. The theoretical Scattering curves were fitted against the experimental SAXS curves using GENFIT software. The software also allows the combination of different theoretical models, in order to better describe the studied system. According to the literature [29, 30] the fitting parameters were set to vary in a specific range, in order to void non-physical results, i.e., R CH 3 was set to vary in the (0.15 nm < R CH 3 < 0.35 nm) range, ρ CH 3 (150 e nm -3 <ρ CH 3 <200 e nm -3 ) andρ par (250 e nm -3 <ρ par < 330 e nm -3 ). It is kwon that in liposomes composed of a mixture of lipids, generally cannot be described. The remaining fitting parameters were allowed to vary in a broader range, in order to ensure a reasonable description of the systems. As it will be shown latter in the text, in the presence of BPQ two distinct fitting models were used to adjust the theoretical scattering function to the experimental data. A more detailed explanation of this model can be found elsewhere [29, 30] . To After 40 days of infection, L. (L.) infantum infected hamsters were treated with nitazoxanide at 2 mg/kg/day for ten consecutives days and the parasite burden was evaluated in the spleen and liver by real-time PCR (qPCR). The drug formulation was able to reduce the parasite burden by 82% (p<0.05) and 50% (p<0.05) in the liver and spleen, respectively. Free drug (NTZ) was used as control and administered for the same period at 100 mg/kg/day. The qPCR data demonstrated a similar parasite burden to untreated control group, demonstrating no efficacy of the free drug (non-liposomal). The untreated group was used for normalization (100% infection) of the parasite burden in spleen and liver (Figure 3 ). In vivo efficacy of free and liposomal nitazoxanide (NTZ-LP) in Leishmania infantum-infected hamsters. The nanoliposomal drug and the free drug (NTZ) were i.p. administered for ten consecutives days at 2 and 100 mg/kg/day, respectively. Real-time PCR was used for quantification of the parasite burden in spleen and liver and the data was normalized based in untreated groups (control groups). *p<0.05 Liposome hydrodynamic diameter, D H , was measured by means of dynamic light scattering, performed in the absence and presence of NTZ. The unilamellar vesicles were prepared with approximately 69% phosphatidylcoline, 21% phosphatidylserine and 10% cholesterol. Figure Figure 4 : SAXS curve of the lipid system in the presence of the drug (black line) along with the best fit obtained in the previously presented model (red line). In the figure, the scattering curves of the system in the absence (black) and presence (red) of the drug. Where w is the weight of the model, R pol and ρ pol as well as R par , ρ par , R CH3 and ρ CH3 are the thicknesses and electronic densities of every single region of the bilayer. Nitazoxanide is an antiparasitic FDA-approved drug with a wide range of therapeutic applications, including antiviral [5, [7] [8] [9] and antiprotozoal activity [12] . It demonstrated activity against L. (L.) mexicana promastigotes and T. cruzi epimastigotes with IC 50 values in the range of 2 and 5 μM [31] . Our previous studies demonstrated that NTZ induced an oxidative stress in Leishmania infantum, causing depolarisation of the mitochondrial membrane and up-regulation of reactive oxygen species (ROS) [32] . Zhang and co-workers [12] demonstrated that NTZ can reduce the parasite burden of Leishmania donovani-infected BALB/c mice by 90% (spleen and liver) after a 10-days treatment at an elevated dose of 400 mg/kg/day. In our studies, NTZ as a free drug (non-liposomal) was administered to Leishmania infantum-infected hamsters and demonstrated no efficacy at the tested dose and regimen. The differences of treatment efficacy of NTZ could be ascribed to the different Leishmania species, dose and regimen of administration (400 mg/kg/day x 100 mg/kg/day), different drug presentation (tablets x free drug), but also to the animal model (mice x hamster). Additionally, it has also been shown that the bioavailability of nitazoxanide is limited due to its poor water solubility [13] , limiting its efficacy in systemic diseases like VL. Considering the need to reduce the dose and consequently, the toxicity, controlled and sustained drug delivery systems (e.g., liposomes) can play a major role. The benefit of a liposomal formulation is related to directing the drug to the target organ, reducing the amount of free drug in the body, thus decreasing its toxicity [17, 18] . Studies published elsewhere have proved that liposomal amphotericin B (Ambisome ® ) shows higher clinical efficacy and safety than the free drug [33] . In this context, nanoliposomes entrapping NTZ were prepared with a negatively infantum-infected mice, demonstrated a slow clearance of the drug in the liver, resulting in sustained levels of the drug after administration [34] . The physicochemical parameters of liposomes as size, surface charge, composition, determine the interaction with targeted cells. In our study, the liposomes vesicles were smaller than 200 nm and had a negative charge on a unilamellar membrane (SUV). Although the drug caused interference in the membrane load, it was not able to modify the membrane, which remained negative after NTZ encapsulation. Physicochemical alterations of liposomal vesicles are described in the literature when encapsulating liposoluble drugs. However, in the present study there were no significant differences in vesicle size when compared to liposomes with and without NTZ, showing no drug interference in the formulation. The number of lamellae is also a considerable factor within a liposomal system, since it can support the amount of encapsulated drug, which means, for fat-soluble drugs the greater number of lamellae, the more the amount of drug encapsulated, theoretically. The interaction of liposomes with target cells is one of the main characteristics to be studied when it is required to design a controlled drug delivery system [19] . The negative charge has been considered an important attribute to explain the efficiency of the formulation [20] . Targeting of phosphatidylserine-liposomes to the mononuclear phagocytic system has been shown to be a promising approach [20, 35] , since scavenger class B receptors (SR-B and CD36) have shown to be the main receptors responsible for their rapid elimination [20] [21] [22] . It should also be highlighted that the size of the liposomes has a strong influence on the uptake by macrophages. The present formulation was based on the preparation of SUVs liposomes, in an attempt to establish a selective and sustained targeting system, since liposomes with a diameter smaller than 200 nm have a lower risk of capillary obstruction when compared to large unilamellar vesicles (LUVs) and multilamellar vesicles (MLVs). important tissue affected by Leishmania infantum parasites [36] . The in vitro kinetics uptake of liposomal nitazoxanide was investigated in naive and L. Visceral Leishmaniasis Leishmaniasis immunopathology-impact on design and use of vaccines, diagnostics and drugs Nitazoxanide: clinical studies of a broad-spectrum antiinfective agent Research perspective: potential role of nitazoxanide in ovarian cancer treatment. Old drug, new purpose? Nitazoxanide: a first-in-class broad-spectrum antiviral agent Treatment with Hydroxychloroquine vs Hydroxychloroquine + Nitazoxanide in COVID-19 patients with risk factors for poor prognosis: A structured summary of a study protocol for a randomised controlled trial Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro US Nitazoxanide Influenza Clinical Study Group. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial Nitazoxanide inhibits HIV viral replication in monocyte-derived macrophages Nitazoxanide: nematicidal mode of action and drug combination studies In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani Laser-responsive liposome for selective tumor targeting of nitazoxanide nanoparticles Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia Loss of orally administered drugs in GI tract Therapeutic applications of colloidal drug carriers Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-J o u r n a l P r e -p r o o f methoxy-3-(4 methoxyphenyl)-1Hindole-2-carboxylate Liposomes in drug delivery: progress and limitations Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages PS-liposome and ox-LDL bind to different sites of the immunodominant domain (#155-183) of CD36: a study with GS95, a new anti-CD36 monoclonal antibody An Improved Colorimetric Assay for Interleukin 2 Fluorescence studies on the mechanism of liposome-cell interactions in vitro RP-HPLC Method for Simultaneous Estimation of Nitazoxanide and Ofloxacin in Tablets Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis In vitro and experimental therapeutic studies of the calcium channel blocker bepridil: detection of viable Leishmania (L.) chagasi by real-time PCR rBPI21 interacts with negative membranes endothermically promoting the formation of rigid multilamellar structures Lamy Influence of salt on the structure of DMPG studied by SAXS and optical microscopy Nitazoxanide, tizoxanide and a new analogue [4-nitro-N-(5-nitro-1,3-thiazol-2-yl)benzamide; NTB] inhibit the growth of kinetoplastid parasites (Trypanosoma cruzi and Leishmania mexicana Lethal action of the nitrothiazolyl-salicylamide derivative nitazoxanide via induction of oxidative stress in Leishmania (L.) infantum Visceral leishmaniasis following treatment with liposomal amphotericin B Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral J o u r n a l P r e -p r o o f leishmaniasis The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids A highly sensitive Leishmania infantum chagasi isolation method from bone marrow and peripheral blood of adults and children SRB1, a class B scavenger receptor, recognizes both negatively charged liposomes and apoptotic cells Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis We also acknowledge Conselho Nacional de Pesquisa e Desenvolvimento (CNPq) for the scientific award to A.G.T and LIPOID GmbH (Ludwigshafen, Germany) for the phospholipids.